Targinta is a preclinical stage oncology biotech company, developing first-in-class therapeutic antibodies and ADCs for treatment of aggressive cancers, such as glioblastoma and triple-negative breast cancer, based on a unique and patent-protected target. The pipeline includes TARG10, which is a function-blocking antibody in preclinical development targeting integrin α10. In addition, Targinta’s pipeline includes TARG9, an antibody-drug conjugate (ADC) targeting integrin α10. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden.